(NewsDirect)
Futura Medical PLC (AIM:FUM, OTC:FAMDF)CEO James Barder tells Proactive's Stephen Gunnion about astrategic shift and refresh for the company in 2023, marked by thesuccessful launch of Eroxon in the UK and Belgium, generating £3.1million in revenues, FDA marketing authorisation in the US, and anexclusive marketing rights deal with Haleon for Eroxon in America.
These achievements have broadenedFutura's global distribution network to approximately 80%,excluding China. The company aims to establish a new sexual healthcategory within the OTC market, leveraging Futura's R&Dexpertise.
The specific launch datein the US with Haleon remains undisclosed due to competitivesensitivities, targeted within a year from the end of February.Pre-launch processes involve ensuring manufacturing capacity, engagingkey opinion leaders, product positioning considering culturalsensitivities, and aligning with retailer schedules.
Objectives for this year include expandinginto at least 14 new countries in the first half, exploringopportunities in Asia, particularly China, and extending Eroxon'sproduct range while focusing on cost management.
Barder,reflecting on Futura's transition from a loss-making R&D firmto a pathway towards profitability, expresses optimism for continuedprogress in 2024.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.